SCHEMBL1815884

SCHEMBL1815884

CC(C)c1cccc(C(C)C)c1C(N)CN

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
SLC6A2 P23975 3/20 0.43
GABRB2 P47870 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
LMNA P02545 2/20 0.43
HTR2C P28335 2/20 0.43
HTR2B P41595 2/20 0.43
FAAH O00519 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
GABRB1 P18505 1/20 0.43
PTGS1 P23219 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1470798 0.80 GABRA1 (0.43) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL29162886 0.77 GABRA1 (0.50) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL814947 0.76 GABRA1 (0.38) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL815487 0.76 GABRA1 (0.38) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL814211 0.76 GABRA1 (0.38) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL813604 0.76 GABRA1 (0.38) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL814562 0.76 GABRA1 (0.38) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL814073 0.76 GABRA1 (0.35) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL66227 0.73 GABRA1 (0.57) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL28723809 0.73 CYP1A2 (0.48) GABRA1GABRG2GABRB3SLC6A2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081790-A Bridged double-center carbene catalyst ligand and preparation method and application thereof 上海化工研究院有限公司 2025-06-03 CN disclosed
CN-115043868-A Five-membered cyclic aminosilane external electron donor, preparation method and application thereof 中国科学院化学研究所 2022-09-13 CN disclosed
EP-3083048-B1 METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST DOW GLOBAL TECHNOLOGIES LLC (US) 2021-04-07 EP disclosed
CN-105813742-B Metal-ligand complex, olefin polymerization catalyst derived therefrom, and olefin polymerization method using the catalyst 陶氏环球技术有限责任公司 2020-05-15 CN disclosed
US-9862734-B2 Metal-ligand complex, olefin polymerization catalyst derived therefrom, and olefin polymerization method utilizing the catalyst DOW GLOBAL TECHNOLOGIES LLC (US) 2018-01-09 US disclosed
CN-104937062-B Binder combination, binding agent, the film including it and its preparation method 3M创新有限公司 2016-12-14 CN disclosed
US-20160311837-A1 METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST DOW GLOBAL TECHNOLOGIES LLC 2016-10-27 US disclosed
EP-3083048-A1 METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST Dow Global Technologies LLC (US) 2016-10-26 EP disclosed
CN-102655935-B Metathesis catalyst and using method thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2016-01-13 CN disclosed
WO-2015094513-A1 METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST DOW GLOBAL TECHNOLOGIES LLC (US) 2015-06-25 WO disclosed
US-9024034-B2 Metathesis catalysts and processes for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-05-05 US disclosed
EP-2498908-A2 METATHESIS CATALYSTS AND PROCESSES FOR USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-19 EP disclosed
WO-2011056874-A2 METATHESIS CATALYSTS AND PROCESSES FOR USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110112302-A1 Metathesis Catalysts and Processes for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112302-A1 Metathesis Catalysts and Processes for Use Thereof FASN, LIPC, MGLL GABRA1 3511/4885GABRG2 3748/4885GABRB3 3494/4885
US-20160311837-A1 METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST OPRM1, WASF2, WEE1 GABRA1 3207/4885GABRG2 3201/4885GABRB3 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.